Currently, there are 293.59M common shares owned by the public and among those 288.09M shares have been available to trade.
The company’s stock has a 5-day price change of -4.89% and -4.71% over the past three months. FOLD shares are trading -27.34% year to date (YTD), with the 12-month market performance down to -24.47% lower. It has a 12-month low price of $9.02 and touched a high of $14.57 over the same period. FOLD has an average intraday trading volume of 2.46 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.09%, 3.22%, and -9.35% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Amicus Therapeutics Inc (NASDAQ: FOLD) shares accounts for 107.03% of the company’s 293.59M shares outstanding.
It has a market capitalization of $3.05B and a beta (3y monthly) value of 0.71. The earnings-per-share (ttm) stands at -$0.50. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.27% over the week and 2.93% over the month.
Earnings per share for the fiscal year are expected to increase by 57.69%, and 197.11% over the next financial year.
Looking at the support for the FOLD, a number of firms have released research notes about the stock. Wells Fargo stated their Overweight rating for the stock in a research note on May 30, 2024, with the firm’s price target at $18. Guggenheim coverage for the Amicus Therapeutics Inc (FOLD) stock in a research note released on May 14, 2024 offered a Buy rating with a price target of $13. Morgan Stanley was of a view on December 19, 2023 that the stock is Overweight, while Morgan Stanley gave the stock Equal-Weight rating on September 09, 2022, issuing a price target of $14. Goldman on their part issued Neutral rating on April 13, 2022.
